{"protocolSection":{"identificationModule":{"nctId":"NCT01955707","orgStudyIdInfo":{"id":"101SK201"},"secondaryIdInfos":[{"id":"EUDRA CT NO: 2013-001514-15"}],"organization":{"fullName":"Biogen","class":"INDUSTRY"},"briefTitle":"Effect of Natalizumab on Infarct Volume in Acute Ischemic Stroke","officialTitle":"A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke","acronym":"ACTION"},"statusModule":{"statusVerifiedDate":"2016-05","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2014-01"},"primaryCompletionDateStruct":{"date":"2015-02","type":"ACTUAL"},"completionDateStruct":{"date":"2015-04","type":"ACTUAL"},"studyFirstSubmitDate":"2013-09-30","studyFirstSubmitQcDate":"2013-09-30","studyFirstPostDateStruct":{"date":"2013-10-07","type":"ESTIMATED"},"resultsFirstSubmitDate":"2016-02-04","resultsFirstSubmitQcDate":"2016-05-24","resultsFirstPostDateStruct":{"date":"2016-07-01","type":"ESTIMATED"},"dispFirstSubmitDate":"2015-08-27","dispFirstSubmitQcDate":"2015-08-27","dispFirstPostDateStruct":{"date":"2015-09-10","type":"ESTIMATED"},"lastUpdateSubmitDate":"2016-05-24","lastUpdatePostDateStruct":{"date":"2016-07-01","type":"ESTIMATED"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Biogen","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":true},"descriptionModule":{"briefSummary":"The primary objective of the study is to determine whether one 300 mg dose of intravenous (IV) natalizumab reduces change in infarct volume from Baseline to Day 5 on magnetic resonance imaging (MRI) in participants with acute ischemic stroke when given at ≤6 hours or at \\>6 to ≤9 hours from when they were last known normal (LKN).\n\nThe secondary objectives of this study in this study population are as follows: to assess the efficacy of natalizumab on change in infarct volume from Baseline to Day 30; to assess efficacy of natalizumab on change in infarct volume from 24 hours to Day 5 and Day 30; to assess the efficacy of natalizumab on clinical measures of stroke outcome; to assess the safety of natalizumab in participants with acute ischemic stroke."},"conditionsModule":{"conditions":["Acute Ischemic Stroke"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":161,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"natalizumab","type":"EXPERIMENTAL","description":"300 mg single intravenous (IV) injection","interventionNames":["Drug: natalizumab"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","description":"A single IV dose of placebo","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"natalizumab","description":"Administered as described in the treatment arm","armGroupLabels":["natalizumab"],"otherNames":["Tysabri","BG00002"]},{"type":"DRUG","name":"Placebo","description":"Matched placebo","armGroupLabels":["Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR])","description":"Relative growth of infarct volume from Baseline (relative growth = FLAIR at Day 5 divided by Baseline DWI). Geometric mean calculated as the exponential of the mean log relative growth.","timeFrame":"Baseline, Day 5"}],"secondaryOutcomes":[{"measure":"Change in Infarct Volume From Baseline (DWI) to 24 Hours (FLAIR)","description":"Relative growth of infarct volume from Baseline (relative growth = FLAIR at 24 hours divided by Baseline DWI). Geometric mean calculated as the exponential of the mean log relative growth.","timeFrame":"Baseline, 24 hrs"},{"measure":"Change in Infarct Volume From Baseline (DWI) to Day 30 (FLAIR)","description":"Relative growth of infarct volume from Baseline (relative growth = FLAIR at Day 30 divided by Baseline DWI). Geometric mean calculated as the exponential of the mean log relative growth.","timeFrame":"Baseline, Day 30"},{"measure":"Change in Infarct Volume From 24 Hours (FLAIR) to Day 5 (FLAIR)","description":"Relative growth of infarct volume from 24 hours (relative growth = FLAIR at Day 5 divided by FLAIR at 24 hours). Geometric mean calculated as the exponential of the mean log relative growth.","timeFrame":"24 hours, Day 5"},{"measure":"Change in Infarct Volume From 24 Hours (FLAIR) to Day 30 (FLAIR)","description":"Relative growth in infarct volume from Baseline (relative growth = FLAIR Day 30 divided by FLAIR at 24 hours ). Geometric mean calculated as the exponential of the mean log relative growth.","timeFrame":"24 hours, Day 30"},{"measure":"Change in Infarct Volume From Day 5 (FLAIR) to Day 30 (FLAIR)","description":"Relative growth of infarct volume from Day 5 (relative growth = FLAIR at Day 30 divided by FLAIR at Day 5). Geometric mean calculated as the exponential of the mean log relative growth.","timeFrame":"Day 5, Day 30"},{"measure":"Change in National Institute of Health Stroke Scale (NIHSS) Score From Baseline to 24 Hours, Day 5, Day 30, and Day 90","description":"The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Scores for the NIHSS range from 0 to 42, with 0 representing no symptoms and 42 representing death.","timeFrame":"Baseline, 24 hours, Day 5, Day 30, Day 90"},{"measure":"Modified Rankin Scale (mRS) Distribution at Day 5, Day 30, and Day 90","description":"The mRS measures independence, rather than neurologic function, with specific tasks pre- and post-stroke, respectively. The scale consists of 7 grades, from 0 to 6, with 0 corresponding to no symptoms and 6 corresponding to death. The distribution of mRS scores was summarized at each timepoint. An excellent outcome on the mRS was defined as a score of 0 or 1, while a good outcome was defined as a score of 0, 1, or 2.","timeFrame":"Day 5, Day 30, and Day 90"},{"measure":"Barthel Index at Day 5, Day 30, and Day 90","description":"The Barthel Index consists of 10 items that measure a person's daily functioning, specifically the activities of daily living and mobility, and can be used to determine a baseline level of functioning and to monitor change in activities of daily living over time. The scores for each of the items are summed to create a total score up to a potential of 100, with higher scores representing a greater level of independence.","timeFrame":"Day 5, Day 30, and Day 90"},{"measure":"Number of Participants Who Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"AE: any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. Events were categorized as severe, moderate, or mild, and related or not related to study treatment.","timeFrame":"Up to Day 90 ± 5 days"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* Diagnosis of acute ischemic stroke.\n* Score of ≥6 points on the National Institute of Health Stroke Scale (NIHSS) at Screening.\n* At least 1 acute infarct with largest diameter of more than 2 cm on Baseline brain diffusion-weighted imaging (DWI).\n* Participants who have received reperfusion therapy may be eligible to participate but must meet all eligibility criteria and perform the Baseline study magnetic resonance imaging (MRI) after reperfusion therapy has been completed.\n* Subjects of childbearing potential must practice effective contraception during the study and be willing and able to continue contraception for at least 3 months after their dose of study treatment.\n\nKey Exclusion Criteria:\n\n* Presence of any intracranial hemorrhage (ICH) on head computed tomography (CT) or non-petechial ICH on screening MRI.\n* Stroke isolated to the brainstem.\n* Presence of coma\n* Expected to die OR unable to be evaluated within 5 days.\n* Hypotension requiring the use of intravenous (IV) vasopressor support or systolic blood pressure \\<90 mmHg at the time of randomization.\n* Known prior treatment with natalizumab.\n* Immunocompromised subjects, as determined by the Investigator.\n* History of progressive multifocal leukoencephalopathy (PML).\n* Contraindications to MRI, e.g., implanted pacemaker or other contraindicated implanted metal devices, history of or risk for side effects from gadolinium, or claustrophobia that cannot be medically managed.\n\nNOTE: Other protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"85 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Medical Director","affiliation":"Biogen","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Research Site","city":"San Diego","state":"California","country":"United States","geoPoint":{"lat":32.71533,"lon":-117.15726}},{"facility":"Research Site","city":"Gainesville","state":"Florida","country":"United States","geoPoint":{"lat":29.65163,"lon":-82.32483}},{"facility":"Research Site","city":"Kansas City","state":"Kansas","zip":"66160","country":"United States","geoPoint":{"lat":39.11417,"lon":-94.62746}},{"facility":"Research Site","city":"Boston","state":"Massachusetts","zip":"02114","country":"United States","geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Research Site","city":"Golden Valley","state":"Minnesota","zip":"55422","country":"United States","geoPoint":{"lat":45.00969,"lon":-93.34912}},{"facility":"Research Site","city":"St. Louis","state":"Missouri","zip":"63110","country":"United States","geoPoint":{"lat":38.62727,"lon":-90.19789}},{"facility":"Research Site","city":"Lake Success","state":"New York","country":"United States","geoPoint":{"lat":40.77066,"lon":-73.71763}},{"facility":"Research Site","city":"New York","state":"New York","zip":"10032","country":"United States","geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Research Site","city":"Durham","state":"North Carolina","zip":"27710","country":"United States","geoPoint":{"lat":35.99403,"lon":-78.89862}},{"facility":"Research Site","city":"Akron","state":"Ohio","country":"United States","geoPoint":{"lat":41.08144,"lon":-81.51901}},{"facility":"Research Site","city":"Dayton","state":"Ohio","zip":"45409","country":"United States","geoPoint":{"lat":39.75895,"lon":-84.19161}},{"facility":"Research Site","city":"Toledo","state":"Ohio","country":"United States","geoPoint":{"lat":41.66394,"lon":-83.55521}},{"facility":"Research Site","city":"Portland","state":"Oregon","country":"United States","geoPoint":{"lat":45.52345,"lon":-122.67621}},{"facility":"Research Site","city":"Tualatin","state":"Oregon","zip":"97062","country":"United States","geoPoint":{"lat":45.38401,"lon":-122.76399}},{"facility":"Research Site","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95233,"lon":-75.16379}},{"facility":"Research Site","city":"Nashville","state":"Tennessee","country":"United States","geoPoint":{"lat":36.16589,"lon":-86.78444}},{"facility":"Research Site","city":"Dallas","state":"Texas","country":"United States","geoPoint":{"lat":32.78306,"lon":-96.80667}},{"facility":"Research Site","city":"Charlottesville","state":"Virginia","country":"United States","geoPoint":{"lat":38.02931,"lon":-78.47668}},{"facility":"Research Site","city":"Milwaukee","state":"Wisconsin","country":"United States","geoPoint":{"lat":43.0389,"lon":-87.90647}},{"facility":"Research Site","city":"Altenburg","zip":"04600","country":"Germany","geoPoint":{"lat":50.98763,"lon":12.43684}},{"facility":"Research Site","city":"Bad Neustadt","zip":"97616","country":"Germany"},{"facility":"Research Site","city":"Berlin","zip":"12203","country":"Germany","geoPoint":{"lat":52.52437,"lon":13.41053}},{"facility":"Research Site","city":"Bonn","country":"Germany","geoPoint":{"lat":50.73438,"lon":7.09549}},{"facility":"Research Site","city":"Duesseldorf","zip":"40225","country":"Germany","geoPoint":{"lat":51.22172,"lon":6.77616}},{"facility":"Research Site","city":"Erlangen","zip":"91054","country":"Germany","geoPoint":{"lat":49.59099,"lon":11.00783}},{"facility":"Research Site","city":"Frankfurt","zip":"60528","country":"Germany","geoPoint":{"lat":50.11552,"lon":8.68417}},{"facility":"Research Site","city":"Hannover","country":"Germany","geoPoint":{"lat":52.37052,"lon":9.73322}},{"facility":"Research Site","city":"Heidelberg","zip":"69120","country":"Germany","geoPoint":{"lat":49.40768,"lon":8.69079}},{"facility":"Research Site","city":"Idar-Oberstein","zip":"55743","country":"Germany","geoPoint":{"lat":49.71443,"lon":7.30776}},{"facility":"Research Site","city":"Leipzig","zip":"04103","country":"Germany","geoPoint":{"lat":51.33962,"lon":12.37129}},{"facility":"Research Site","city":"Ludwigshafen","zip":"67063","country":"Germany","geoPoint":{"lat":49.48121,"lon":8.44641}},{"facility":"Research Site","city":"Ludwigshafen","country":"Germany","geoPoint":{"lat":49.48121,"lon":8.44641}},{"facility":"Research Site","city":"Mannheim","country":"Germany","geoPoint":{"lat":49.4891,"lon":8.46694}},{"facility":"Research Site","city":"Trier","zip":"54290","country":"Germany","geoPoint":{"lat":49.75565,"lon":6.63935}},{"facility":"Research Site","city":"Tübingen","zip":"72076","country":"Germany","geoPoint":{"lat":48.52266,"lon":9.05222}},{"facility":"Research Site","city":"Ulm","country":"Germany","geoPoint":{"lat":48.39841,"lon":9.99155}},{"facility":"Research Site","city":"Albacete","zip":"02006","country":"Spain","geoPoint":{"lat":38.99424,"lon":-1.85643}},{"facility":"Research Site","city":"Badalona","zip":"8916","country":"Spain","geoPoint":{"lat":41.45004,"lon":2.24741}},{"facility":"Research Site","city":"Barakaldo","country":"Spain","geoPoint":{"lat":43.29639,"lon":-2.98813}},{"facility":"Research Site","city":"Barcelona","zip":"8003","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Barcelona","zip":"8035","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Barcelona","zip":"8036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Research Site","city":"Girona","zip":"17007","country":"Spain","geoPoint":{"lat":41.98311,"lon":2.82493}},{"facility":"Research Site","city":"Madrid","zip":"28034","country":"Spain","geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"Research Site","city":"Pamplona","zip":"31008","country":"Spain","geoPoint":{"lat":42.81687,"lon":-1.64323}},{"facility":"Research Site","city":"Santiago de Compostela","zip":"15706","country":"Spain","geoPoint":{"lat":42.88052,"lon":-8.54569}},{"facility":"Research Site","city":"Sevilla","zip":"41009","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Research Site","city":"Valencia","country":"Spain","geoPoint":{"lat":39.46975,"lon":-0.37739}},{"facility":"Research Site","city":"Valladolid","zip":"47005","country":"Spain","geoPoint":{"lat":41.65518,"lon":-4.72372}}]},"referencesModule":{"references":[{"pmid":"28229893","type":"DERIVED","citation":"Elkins J, Veltkamp R, Montaner J, Johnston SC, Singhal AB, Becker K, Lansberg MG, Tang W, Chang I, Muralidharan K, Gheuens S, Mehta L, Elkind MSV. Safety and efficacy of natalizumab in patients with acute ischaemic stroke (ACTION): a randomised, placebo-controlled, double-blind phase 2 trial. Lancet Neurol. 2017 Mar;16(3):217-226. doi: 10.1016/S1474-4422(16)30357-X. Epub 2017 Feb 15."}]}},"resultsSection":{"participantFlowModule":{"groups":[{"id":"FG000","title":"Placebo","description":"A single intravenous (IV) injection of placebo"},{"id":"FG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"79"}]},{"type":"Withdrew Prior to Dosing","achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Dosed","achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"78"}]},{"type":"Received Total Volume of Study Drug","achievements":[{"groupId":"FG000","numSubjects":"82"},{"groupId":"FG001","numSubjects":"77"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"62"},{"groupId":"FG001","numSubjects":"57"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"20"},{"groupId":"FG001","numSubjects":"22"}]}],"dropWithdraws":[{"type":"Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"2"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"3"}]},{"type":"Death","reasons":[{"groupId":"FG000","numSubjects":"13"},{"groupId":"FG001","numSubjects":"14"}]},{"type":"Other","reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"BG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"},{"id":"BG002","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"82"},{"groupId":"BG001","value":"79"},{"groupId":"BG002","value":"161"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"71.6","spread":"11.83"},{"groupId":"BG001","value":"70.3","spread":"13.34"},{"groupId":"BG002","value":"71.0","spread":"12.57"}]}]}]},{"title":"Age, Customized","paramType":"NUMBER","unitOfMeasure":"participants","classes":[{"title":"</= 39 years","categories":[{"measurements":[{"groupId":"BG000","value":"2"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"5"}]}]},{"title":"40 to 59 years","categories":[{"measurements":[{"groupId":"BG000","value":"13"},{"groupId":"BG001","value":"11"},{"groupId":"BG002","value":"24"}]}]},{"title":"60 to 79 years","categories":[{"measurements":[{"groupId":"BG000","value":"41"},{"groupId":"BG001","value":"45"},{"groupId":"BG002","value":"86"}]}]},{"title":">/= 80 years","categories":[{"measurements":[{"groupId":"BG000","value":"26"},{"groupId":"BG001","value":"20"},{"groupId":"BG002","value":"46"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"34"},{"groupId":"BG001","value":"38"},{"groupId":"BG002","value":"72"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"48"},{"groupId":"BG001","value":"41"},{"groupId":"BG002","value":"89"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Infarct Volume From Baseline (Diffusion-Weighted Imaging [DWI]) to Day 5 (Fluid-Attenuated Inversion Recovery [FLAIR])","description":"Relative growth of infarct volume from Baseline (relative growth = FLAIR at Day 5 divided by Baseline DWI). Geometric mean calculated as the exponential of the mean log relative growth.","populationDescription":"Modified intention to treat (all participants who were randomized and received the entire infusion of study treatment) with assessments at both time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"mL","timeFrame":"Baseline, Day 5","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"73"},{"groupId":"OG001","value":"69"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.17","lowerLimit":"1.60","upperLimit":"3.17"},{"groupId":"OG001","value":"2.37","lowerLimit":"1.51","upperLimit":"2.91"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment contrasts derived from a repeated measures mixed effects model modeling log relative growth relative to baseline using an autoregressive variance-covariance matrix structure. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, and tissue plasminogen activator (tPA) use.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"adjusted mean difference (log-scale)","paramValue":"0.08","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.09","ciUpperLimit":"0.26"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.779","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"ratio of relative growth","paramValue":"1.09","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.91","ciUpperLimit":"1.30","estimateComment":"Adjusted mean (log-scale) back-transformed to the original scale as the estimated ratio of natalizumab to placebo. 90% confidence interval (log-scale) back-transformed to the original scale and reflect the interval around the ratio."}]},{"type":"SECONDARY","title":"Change in Infarct Volume From Baseline (DWI) to 24 Hours (FLAIR)","description":"Relative growth of infarct volume from Baseline (relative growth = FLAIR at 24 hours divided by Baseline DWI). Geometric mean calculated as the exponential of the mean log relative growth.","populationDescription":"Modified intention to treat (all participants who were randomized and received the entire infusion of study treatment) with assessments at both time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"mL","timeFrame":"Baseline, 24 hrs","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"69"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.73","lowerLimit":"1.33","upperLimit":"2.15"},{"groupId":"OG001","value":"1.95","lowerLimit":"1.36","upperLimit":"2.20"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment contrasts derived from a repeated measures mixed effects model modeling log relative growth relative to baseline using an autoregressive variance-covariance matrix structure. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, and tPA use.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"adjusted mean difference (log-scale)","paramValue":"0.09","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.09","ciUpperLimit":"0.27"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.797","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"ratio of relative growth","paramValue":"1.09","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.92","ciUpperLimit":"1.31","estimateComment":"Adjusted mean (log-scale) back-transformed to the original scale as the estimated ratio of natalizumab to placebo. 90% confidence interval (log-scale) back-transformed to the original scale and reflect the interval around the ratio."}]},{"type":"SECONDARY","title":"Change in Infarct Volume From Baseline (DWI) to Day 30 (FLAIR)","description":"Relative growth of infarct volume from Baseline (relative growth = FLAIR at Day 30 divided by Baseline DWI). Geometric mean calculated as the exponential of the mean log relative growth.","populationDescription":"Modified intention to treat (all participants who were randomized and received the entire infusion of study treatment) with assessments at both time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"mL","timeFrame":"Baseline, Day 30","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"66"},{"groupId":"OG001","value":"55"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","lowerLimit":"0.90","upperLimit":"1.88"},{"groupId":"OG001","value":"1.25","lowerLimit":"0.78","upperLimit":"1.93"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment contrasts derived from a repeated measures mixed effects model modeling log relative growth relative to baseline using an autoregressive variance-covariance matrix structure. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, and tPA use.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Adjusted mean difference (log-scale)","paramValue":"0.05","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.13","ciUpperLimit":"0.24"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.684","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"ratio of relative growth","paramValue":"1.05","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.88","ciUpperLimit":"1.27","estimateComment":"Adjusted mean (log-scale) back-transformed to the original scale as the estimated ratio of natalizumab to placebo. 90% confidence interval (log-scale) back-transformed to the original scale and reflect the interval around the ratio."}]},{"type":"SECONDARY","title":"Change in Infarct Volume From 24 Hours (FLAIR) to Day 5 (FLAIR)","description":"Relative growth of infarct volume from 24 hours (relative growth = FLAIR at Day 5 divided by FLAIR at 24 hours). Geometric mean calculated as the exponential of the mean log relative growth.","populationDescription":"Modified intention to treat (all participants who were randomized and received the entire infusion of study treatment) with assessments at both time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"mL","timeFrame":"24 hours, Day 5","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"70"},{"groupId":"OG001","value":"65"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.27","lowerLimit":"1.11","upperLimit":"1.37"},{"groupId":"OG001","value":"1.25","lowerLimit":"1.11","upperLimit":"1.42"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment contrasts derived from a repeated measures mixed effects model modeling log relative growth relative to 24 hours using an autoregressive variance-covariance matrix structure. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, and tPA use.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Adjusted mean difference (log-scale)","paramValue":"-0.00","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.12","ciUpperLimit":"0.11"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.487","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"ratio of relative growth","paramValue":"1.00","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.89","ciUpperLimit":"1.12","estimateComment":"Adjusted mean (log-scale) back-transformed to the original scale as the estimated ratio of natalizumab to placebo. 90% confidence interval (log-scale) back-transformed to the original scale and reflect the interval around the ratio."}]},{"type":"SECONDARY","title":"Change in Infarct Volume From 24 Hours (FLAIR) to Day 30 (FLAIR)","description":"Relative growth in infarct volume from Baseline (relative growth = FLAIR Day 30 divided by FLAIR at 24 hours ). Geometric mean calculated as the exponential of the mean log relative growth.","populationDescription":"Modified intention to treat (all participants who were randomized and received the entire infusion of study treatment) with assessments at both time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"mL","timeFrame":"24 hours, Day 30","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"53"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.75","lowerLimit":"0.62","upperLimit":"1.03"},{"groupId":"OG001","value":"0.72","lowerLimit":"0.56","upperLimit":"1.09"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment contrasts derived from a repeated measures mixed effects model modeling log relative growth relative to 24 hours using an autoregressive variance-covariance matrix structure. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, and tPA use.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Adjusted mean difference (log-scale)","paramValue":"-0.02","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.14","ciUpperLimit":"0.10"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.402","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"ratio of relative growth","paramValue":"0.98","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.87","ciUpperLimit":"1.11","estimateComment":"Adjusted mean (log-scale) back-transformed to the original scale as the estimated ratio of natalizumab to placebo. 90% confidence interval (log-scale) back-transformed to the original scale and reflect the interval around the ratio."}]},{"type":"SECONDARY","title":"Change in Infarct Volume From Day 5 (FLAIR) to Day 30 (FLAIR)","description":"Relative growth of infarct volume from Day 5 (relative growth = FLAIR at Day 30 divided by FLAIR at Day 5). Geometric mean calculated as the exponential of the mean log relative growth.","populationDescription":"Modified intention to treat (all participants who were randomized and received the entire infusion of study treatment) with assessments at both time points.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"Inter-Quartile Range","unitOfMeasure":"mL","timeFrame":"Day 5, Day 30","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"64"},{"groupId":"OG001","value":"54"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","lowerLimit":"0.52","upperLimit":"0.79"},{"groupId":"OG001","value":"0.59","lowerLimit":"0.42","upperLimit":"0.81"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Treatment contrasts derived from a repeated measures mixed effects model modeling log relative growth relative to Day 5 using an autoregressive variance-covariance matrix structure. The model adjusts for for treatment, log baseline DWI volume, treatment time window, and tPA use.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","paramType":"Adjusted mean difference (log-scale)","paramValue":"-0.02","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.18","ciUpperLimit":"0.13"},{"groupIds":["OG000","OG001"],"testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.394","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"ratio of relative growth","paramValue":"0.98","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.84","ciUpperLimit":"1.14","estimateComment":"Adjusted mean (log-scale) back-transformed to the original scale as the estimated ratio of natalizumab to placebo. 90% confidence interval (log-scale) back-transformed to the original scale and reflect the interval around the ratio."}]},{"type":"SECONDARY","title":"Change in National Institute of Health Stroke Scale (NIHSS) Score From Baseline to 24 Hours, Day 5, Day 30, and Day 90","description":"The NIHSS is a systematic assessment tool that provides a quantitative measure of stroke-related neurologic deficit. Scores for the NIHSS range from 0 to 42, with 0 representing no symptoms and 42 representing death.","populationDescription":"Modified intention to treat (all participants who were randomized and received the entire infusion of study treatment); n=participants with assessments at Baseline and given time point.","reportingStatus":"POSTED","paramType":"MEAN","dispersionType":"Standard Deviation","unitOfMeasure":"units on a scale","timeFrame":"Baseline, 24 hours, Day 5, Day 30, Day 90","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"77"}]}],"classes":[{"title":"Change at 24 hours; n=82, 77","categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"3.96"},{"groupId":"OG001","value":"-1.5","spread":"5.10"}]}]},{"title":"Change at Day 5; n=79, 72","categories":[{"measurements":[{"groupId":"OG000","value":"-3.3","spread":"5.31"},{"groupId":"OG001","value":"-2.1","spread":"6.24"}]}]},{"title":"Change at Day 30; n=73, 62","categories":[{"measurements":[{"groupId":"OG000","value":"-5.7","spread":"5.22"},{"groupId":"OG001","value":"-4.9","spread":"5.73"}]}]},{"title":"Change at Day 90; n=62, 56","categories":[{"measurements":[{"groupId":"OG000","value":"-7.3","spread":"3.95"},{"groupId":"OG001","value":"-6.8","spread":"5.78"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of NIHSS score and change from Baseline at 24 hours. The repeated measures mixed effects model is modeling absolute change in NIHSS score relative to baseline and using an autoregressive variance-covariance matrix. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, tPA use, baseline NIHSS score and location of stroke.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.427","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"adjusted mean change from baseline","paramValue":"-0.25","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-2.48","ciUpperLimit":"1.98"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of NIHSS score and change from Baseline at Day 5. The repeated measures mixed effects model is modeling absolute change in NIHSS score relative to baseline and using an autoregressive variance-covariance matrix. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, tPA use, baseline NIHSS score and location of stroke.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.896","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"adjusted mean change from baseline","paramValue":"1.71","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.52","ciUpperLimit":"3.94"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of NIHSS score and change from Baseline at Day 30. The repeated measures mixed effects model is modeling absolute change in NIHSS score relative to baseline and using an autoregressive variance-covariance matrix. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, tPA use, baseline NIHSS score and location of stroke.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.989","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"adjusted mean change from baseline","paramValue":"3.15","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.89","ciUpperLimit":"5.40"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of NIHSS score and change from Baseline at Day 90. The repeated measures mixed effects model is modeling absolute change in NIHSS score relative to baseline and using an autoregressive variance-covariance matrix. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, tPA use, baseline NIHSS score and location of stroke.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.915","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"adjusted mean change from baseline","paramValue":"1.93","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-0.38","ciUpperLimit":"4.25"}]},{"type":"SECONDARY","title":"Modified Rankin Scale (mRS) Distribution at Day 5, Day 30, and Day 90","description":"The mRS measures independence, rather than neurologic function, with specific tasks pre- and post-stroke, respectively. The scale consists of 7 grades, from 0 to 6, with 0 corresponding to no symptoms and 6 corresponding to death. The distribution of mRS scores was summarized at each timepoint. An excellent outcome on the mRS was defined as a score of 0 or 1, while a good outcome was defined as a score of 0, 1, or 2.","populationDescription":"Modified intention to treat (all participants who were randomized and received the entire infusion of study treatment), using imputed data; n=number of participants with an assessment at given time point.","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Day 5, Day 30, and Day 90","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"77"}]}],"classes":[{"title":"Day 5: Score 0; n=82, 76","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"}]}]},{"title":"Day 5: Score 1; n=82, 76","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"}]}]},{"title":"Day 5: Score 2; n=82, 76","categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"11"}]}]},{"title":"Day 5: Score 3; n=82, 76","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"11"}]}]},{"title":"Day 5: Score 4; n=82, 76","categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"16"}]}]},{"title":"Day 5: Score 5; n=82, 76","categories":[{"measurements":[{"groupId":"OG000","value":"29"},{"groupId":"OG001","value":"31"}]}]},{"title":"Day 5: Score 6; n=82, 76","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"}]}]},{"title":"Day 30: Score 0; n=81, 72","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"5"}]}]},{"title":"Day 30: Score 1; n=81, 72","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"8"}]}]},{"title":"Day 30: Score 2; n=81, 72","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"8"}]}]},{"title":"Day 30: Score 3; n=81, 72","categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"17"}]}]},{"title":"Day 30: Score 4; n=81, 72","categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"14"}]}]},{"title":"Day 30: Score 5; n=81, 72","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"11"}]}]},{"title":"Day 30: Score 6; n=81, 72","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"9"}]}]},{"title":"Day 90: Score 0; n=78, 72","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"8"}]}]},{"title":"Day 90: Score 1; n=78, 72","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"}]}]},{"title":"Day 90: Score 2; n=78, 72","categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"10"}]}]},{"title":"Day 90: Score 3; n=78, 72","categories":[{"measurements":[{"groupId":"OG000","value":"15"},{"groupId":"OG001","value":"13"}]}]},{"title":"Day 90: Score 4; n=78, 72","categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"11"}]}]},{"title":"Day 90: Score 5; n=78, 72","categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"}]}]},{"title":"Day 90: Score 6; n=78, 72","categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"14"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of distribution of mRS scores at Day 5. Odds ratio from a proportional-odds logistic regression model assuming a common odds ratio across all cut points of the mRS score. Covariates include baseline DWI volume (\\< median vs \\>= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.564","pValueComment":"One sided p-value based on Van Elteren's test, adjusting for baseline DWI volume (\\< median vs \\>= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).","statisticalMethod":"Van Elteren's test","paramType":"Odds Ratio (OR)","paramValue":"0.89","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.55","ciUpperLimit":"1.45"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of distribution of mRS scores at Day 30. Odds ratio from a proportional-odds logistic regression model assuming a common odds ratio across all cut points of the mRS score. Covariates include baseline DWI volume (\\< median vs \\>= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.077","pValueComment":"One-sided p-value based on Van Elteren's test, adjusting for baseline DWI volume (\\< median vs \\>= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).","statisticalMethod":"Van Elteren's test","paramType":"Odds Ratio (OR)","paramValue":"1.30","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.80","ciUpperLimit":"2.10"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of the distribution of mRS scores at Day 90. Odds ratio from a proportional-odds logistic regression model assuming a common odds ratio across all cut points of the mRS score. Covariates include baseline DWI volume (\\< median vs \\>= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.243","pValueComment":"One -sided p-value based on Van Elteren's test, adjusting for baseline DWI volume (\\< median vs \\>= median), treatment time window, location of stroke abnormality (cortical/subcortical), and tPA use (yes/no).","statisticalMethod":"Van Elteren's test","paramType":"Odds Ratio (OR)","paramValue":"1.15","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"0.71","ciUpperLimit":"1.86"}]},{"type":"SECONDARY","title":"Barthel Index at Day 5, Day 30, and Day 90","description":"The Barthel Index consists of 10 items that measure a person's daily functioning, specifically the activities of daily living and mobility, and can be used to determine a baseline level of functioning and to monitor change in activities of daily living over time. The scores for each of the items are summed to create a total score up to a potential of 100, with higher scores representing a greater level of independence.","populationDescription":"Modified intention to treat (all participants who were randomized and received the entire infusion of study treatment); n=participants with assessment at given time point.","reportingStatus":"POSTED","paramType":"MEDIAN","dispersionType":"Full Range","unitOfMeasure":"units on a scale","timeFrame":"Day 5, Day 30, and Day 90","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"77"}]}],"classes":[{"title":"Day 5; n=78, 73","categories":[{"measurements":[{"groupId":"OG000","value":"35.0","lowerLimit":"0","upperLimit":"100"},{"groupId":"OG001","value":"30.0","lowerLimit":"0","upperLimit":"100"}]}]},{"title":"Day 30; n=73, 60","categories":[{"measurements":[{"groupId":"OG000","value":"70.0","lowerLimit":"0","upperLimit":"100"},{"groupId":"OG001","value":"80.0","lowerLimit":"0","upperLimit":"100"}]}]},{"title":"Day 90; n=61, 55","categories":[{"measurements":[{"groupId":"OG000","value":"80.0","lowerLimit":"0","upperLimit":"100"},{"groupId":"OG001","value":"95.0","lowerLimit":"0","upperLimit":"100"}]}]}],"analyses":[{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of Barthel Index at Day 5. The repeated measures mixed effects model is modeling Barthel Index using an autoregressive variance-covariance matrix. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, tPA use, and location of stroke.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.455","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"Adjusted mean","paramValue":"0.68","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-9.19","ciUpperLimit":"10.56"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of Barthel Index at Day 30. The repeated measures mixed effects model is modeling Barthel Index using an autoregressive variance-covariance matrix. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, tPA use, and location of stroke.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.420","pValueComment":"one-sided p-value","statisticalMethod":"repeated measures mixed effects model","paramType":"Adjusted mean","paramValue":"1.21","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-8.76","ciUpperLimit":"11.19"},{"groupIds":["OG000","OG001"],"groupDescription":"Analysis of Barthel Index at Day 90/Final Visit. The repeated measures mixed effects model is modeling Barthel Index using an autoregressive variance-covariance matrix. The model adjusts for treatment, time, treatment by time, log baseline DWI volume, treatment time window, tPA use, and location of stroke.","testedNonInferiority":false,"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.283","statisticalMethod":"repeated measures mixed effects model","paramType":"Adjusted mean","paramValue":"3.56","ciPctValue":"90","ciNumSides":"TWO_SIDED","ciLowerLimit":"-6.64","ciUpperLimit":"13.75"}]},{"type":"SECONDARY","title":"Number of Participants Who Experience Adverse Events (AEs) and Serious Adverse Events (SAEs)","description":"AE: any untoward medical occurrence that does not necessarily have a causal relationship with this treatment. SAE: any untoward medical occurrence that at any dose: results in death; in the view of the Investigator, places the participant at immediate risk of death (a life-threatening event); requires inpatient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; results in a congenital anomaly/birth defect; any other medically important event that, in the opinion of the Investigator, may jeopardize the participant or may require intervention to prevent one of the other outcomes listed in the definition above. Events were categorized as severe, moderate, or mild, and related or not related to study treatment.","populationDescription":"Safety population (all participants who were randomized and received any portion of the infusion of study treatment).","reportingStatus":"POSTED","paramType":"NUMBER","unitOfMeasure":"participants","timeFrame":"Up to Day 90 ± 5 days","groups":[{"id":"OG000","title":"Placebo","description":"A single IV injection of placebo"},{"id":"OG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab"}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"82"},{"groupId":"OG001","value":"78"}]}],"classes":[{"title":"Participants with an event","categories":[{"measurements":[{"groupId":"OG000","value":"81"},{"groupId":"OG001","value":"77"}]}]},{"title":"Participants with a moderate or severe event","categories":[{"measurements":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"53"}]}]},{"title":"Participants with a severe event","categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"22"}]}]},{"title":"Participants with a related event","categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"}]}]},{"title":"Participants with a serious event","categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"36"}]}]},{"title":"Participants discontinuing due to an event","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}]}]},{"title":"Participants withdrawing from study due to event","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"From informed consent (SAE) or initiation of study drug (AE) until Final Visit Day 90 ± 5 days or early termination follow-up.","eventGroups":[{"id":"EG000","title":"Placebo","description":"A single IV injection of placebo","seriousNumAffected":38,"seriousNumAtRisk":82,"otherNumAffected":75,"otherNumAtRisk":82},{"id":"EG001","title":"Natalizumab","description":"300 mg single IV injection of natalizumab","seriousNumAffected":36,"seriousNumAtRisk":78,"otherNumAffected":68,"otherNumAtRisk":78}],"seriousEvents":[{"term":"Splenic haemorrhage","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Acute myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Cardiac arrest","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Cardiac failure","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Cardiac failure chronic","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Intracardiac thrombus","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Myocardial infarction","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Pulseless electrical activity","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Ventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Toxic nodular goitre","organSystem":"Endocrine disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Death","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Device dislocation","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Multi-organ failure","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":2,"numAtRisk":78}]},{"term":"Cholecystitis acute","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Diverticulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Endocarditis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Influenza","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":3,"numAtRisk":78}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Septic shock","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Urinary tract infection pseudomonal","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Avulsion fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Brain herniation","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Femur fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Dehydration","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Cholangiocarcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Glioma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Basilar artery thrombosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Brain midline shift","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Carotid artery stenosis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":3,"numAtRisk":78}]},{"term":"Cerebral infarction","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Cerebral ischaemia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Cerebrovascular accident","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":2,"numAtRisk":78}]},{"term":"Convulsion","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":2,"numAtRisk":78}]},{"term":"Dementia","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Dementia alzheimer's type","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Encephalopathy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Generalised non-convulsive epilepsy","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Haemorrhage intracranial","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Haemorrhagic transformation stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Intracranial pressure increased","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Ischaemic stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Nervous system disorder","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Neurological decompensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Partial seizures","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Stroke in evolution","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":2,"numAtRisk":78}]},{"term":"Subdural hygroma","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Vocal cord paralysis","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Aggression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Delirium","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Renal failure","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Renal failure chronic","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Acute respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Pneumonia aspiration","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Respiratory distress","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Respiratory failure","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":2,"numAtRisk":78}]},{"term":"Endarterectomy","organSystem":"Surgical and medical procedures","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Peripheral embolism","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]},{"term":"Peripheral ischaemia","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":0,"numAtRisk":78}]}],"otherEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":82},{"groupId":"EG001","numAffected":8,"numAtRisk":78}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":82},{"groupId":"EG001","numAffected":7,"numAtRisk":78}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":82},{"groupId":"EG001","numAffected":1,"numAtRisk":78}]},{"term":"Tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":82},{"groupId":"EG001","numAffected":3,"numAtRisk":78}]},{"term":"Constipation","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":23,"numAtRisk":82},{"groupId":"EG001","numAffected":24,"numAtRisk":78}]},{"term":"Nausea","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":11,"numAtRisk":82},{"groupId":"EG001","numAffected":9,"numAtRisk":78}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":15,"numAtRisk":82},{"groupId":"EG001","numAffected":5,"numAtRisk":78}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":82},{"groupId":"EG001","numAffected":9,"numAtRisk":78}]},{"term":"Pyrexia","organSystem":"General disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":26,"numAtRisk":82},{"groupId":"EG001","numAffected":32,"numAtRisk":78}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":82},{"groupId":"EG001","numAffected":10,"numAtRisk":78}]},{"term":"Respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":9,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":82},{"groupId":"EG001","numAffected":19,"numAtRisk":78}]},{"term":"Fall","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":82},{"groupId":"EG001","numAffected":8,"numAtRisk":78}]},{"term":"Alanine aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":5,"numAtRisk":78}]},{"term":"Aspartate aminotransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Gamma-glutamyltransferase increased","organSystem":"Investigations","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Diabetes mellitus","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Hypercholesterolaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":82},{"groupId":"EG001","numAffected":6,"numAtRisk":78}]},{"term":"Hyperglycaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":82},{"groupId":"EG001","numAffected":9,"numAtRisk":78}]},{"term":"Hypokalaemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":82},{"groupId":"EG001","numAffected":10,"numAtRisk":78}]},{"term":"Hyponatraemia","organSystem":"Metabolism and nutrition disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":5,"numAtRisk":82},{"groupId":"EG001","numAffected":3,"numAtRisk":78}]},{"term":"Back pain","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Pain in extremity","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":4,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Brain oedema","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":82},{"groupId":"EG001","numAffected":6,"numAtRisk":78}]},{"term":"Cerebral haemorrhage","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":0,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Haemorrhagic transformation stroke","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":21,"numAtRisk":82},{"groupId":"EG001","numAffected":18,"numAtRisk":78}]},{"term":"Headache","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":19,"numAtRisk":82},{"groupId":"EG001","numAffected":13,"numAtRisk":78}]},{"term":"Neurological decompensation","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Somnolence","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Agitation","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":3,"numAtRisk":82},{"groupId":"EG001","numAffected":11,"numAtRisk":78}]},{"term":"Anxiety","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":1,"numAtRisk":82},{"groupId":"EG001","numAffected":6,"numAtRisk":78}]},{"term":"Depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":82},{"groupId":"EG001","numAffected":5,"numAtRisk":78}]},{"term":"Insomnia","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":13,"numAtRisk":82},{"groupId":"EG001","numAffected":7,"numAtRisk":78}]},{"term":"Post stroke depression","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":2,"numAtRisk":82},{"groupId":"EG001","numAffected":4,"numAtRisk":78}]},{"term":"Sleep disorder","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":7,"numAtRisk":82},{"groupId":"EG001","numAffected":8,"numAtRisk":78}]},{"term":"Urinary retention","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":6,"numAtRisk":82},{"groupId":"EG001","numAffected":5,"numAtRisk":78}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":10,"numAtRisk":82},{"groupId":"EG001","numAffected":15,"numAtRisk":78}]},{"term":"Hypotension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 17.1","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numAffected":12,"numAtRisk":82},{"groupId":"EG001","numAffected":2,"numAtRisk":78}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"Our agreement is subject to confidentiality but generally the PI can publish, for noncommercial purposes only, results and methods of the trial, but no other Sponsor Confidential Information. PI must give Sponsor no less than 60 days to review any manuscript for a proposed publication and must delay publication for up to an additional 90 days thereafter if Sponsor needs to file any patent application to protect any of Sponsor's intellectual property contained in the proposed publication."},"pointOfContact":{"title":"Biogen Study Medical Director","organization":"Biogen","email":"clinicaltrials@biogen.com"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000020521","term":"Stroke"},{"id":"D000083242","term":"Ischemic Stroke"},{"id":"D000002544","term":"Cerebral Infarction"},{"id":"D000007511","term":"Ischemia"}],"ancestors":[{"id":"D000002561","term":"Cerebrovascular Disorders"},{"id":"D000001927","term":"Brain Diseases"},{"id":"D000002493","term":"Central Nervous System Diseases"},{"id":"D000009422","term":"Nervous System Diseases"},{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000020520","term":"Brain Infarction"},{"id":"D000002545","term":"Brain Ischemia"},{"id":"D000007238","term":"Infarction"},{"id":"D000009336","term":"Necrosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","asFound":"Stroke","relevance":"HIGH"},{"id":"M10233","name":"Ischemia","asFound":"Ischemic","relevance":"HIGH"},{"id":"M2401","name":"Ischemic Stroke","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M9972","name":"Infarction","relevance":"LOW"},{"id":"M5483","name":"Cerebral Infarction","asFound":"Ischemic Stroke","relevance":"HIGH"},{"id":"M5500","name":"Cerebrovascular Disorders","relevance":"LOW"},{"id":"M4894","name":"Brain Diseases","relevance":"LOW"},{"id":"M5432","name":"Central Nervous System Diseases","relevance":"LOW"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M21995","name":"Brain Infarction","relevance":"LOW"},{"id":"M5484","name":"Brain Ischemia","relevance":"LOW"},{"id":"M11974","name":"Necrosis","relevance":"LOW"},{"id":"T170","name":"Acute Graft Versus Host Disease","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"},{"abbrev":"Rare","name":"Rare Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069442","term":"Natalizumab"}],"ancestors":[{"id":"D000007155","term":"Immunologic Factors"},{"id":"D000045505","term":"Physiological Effects of Drugs"}],"browseLeaves":[{"id":"M411","name":"Natalizumab","asFound":"Adult diffuse small cleaved cell lymphoma","relevance":"HIGH"},{"id":"M9891","name":"Immunologic Factors","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"}]}},"hasResults":true}